	US 11,686,735 B2
	Systems and methods to identify and treat subjects at risk for obstetrical complications
Tinnakorn Chaiworapongsa, Grosse Pointe Park, MI (US); Roberto Romero, Grosse Pointe, MI (US); and Sonia S. Hassan, Novi, MI (US)
Assigned to WAYNE STATE UNIVERSITY, Detroit, MI (US); and THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Bethesda, MD (US)
Filed by Wayne State University, Detroit, MI (US); and The United States of America as Represented by the Secretary, Department of Health and Human Service, Bethesda, MD (US)
Filed on Apr. 17, 2019, as Appl. No. 16/387,486.
Application 16/387,486 is a division of application No. 15/129,771, granted, now 10,281,475, previously published as PCT/US2015/023117, filed on Mar. 27, 2015.
Claims priority of provisional application 61/971,486, filed on Mar. 27, 2014.
Prior Publication US 2019/0285643 A1, Sep. 19, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/53 (2006.01); G01N 33/68 (2006.01); C12Q 1/6883 (2018.01); G16H 10/40 (2018.01); G16H 50/30 (2018.01); A61K 31/22 (2006.01); A61K 31/616 (2006.01); A61K 31/727 (2006.01); G16H 20/10 (2018.01)

CPC G01N 33/689 (2013.01) [A61K 31/22 (2013.01); A61K 31/616 (2013.01); A61K 31/727 (2013.01); C12Q 1/6883 (2013.01); G01N 33/6872 (2013.01); G16H 10/40 (2018.01); G16H 20/10 (2018.01); G16H 50/30 (2018.01); C12Q 2600/158 (2013.01); G01N 2333/475 (2013.01); G01N 2333/912 (2013.01); G01N 2800/368 (2013.01); G01N 2800/50 (2013.01)]

16 Claims

1. A method of treating an angiogenic and anti-angiogenic imbalance in a female human subject comprising:

identifying the subject as having or at risk of the angiogenic and anti-angiogenic imbalance by a method comprising:

obtaining a sample derived from the subject;

assaying the sample for the concentration of PIGF and sVEGFR-1;

analyzing the concentrations by assessing a ratio of PIGF/sVEGFR-1 in the sample;

determining a Multiples of the Median (MoM) maternal plasma concentration ratio of PIGF/sVEGFR-1;

comparing the determined MoM maternal plasma concentration ratio to a threshold; and

identifying the subject as having or at risk of an angiogenic and anti-angiogenic imbalance based on the comparison of the MoM maternal plasma concentration ratio to the threshold, wherein a MoM concentration of <0.12 for PIGF/sVEGFR-1 is indicative of an angiogenic and anti-angiogenic imbalance; and

administering an effective amount of a water-soluble statin to the subject, thereby treating the angiogenic and anti-angiogenic imbalance.